Company Overview

Adagene Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The company operates within the biopharmaceutical and oncology immunotherapy industries, leveraging proprietary computational biology and antibody engineering platforms to address unmet needs in cancer treatment. Its core strategy centers on designing differentiated antibodies with enhanced safety and efficacy profiles, particularly for solid tumors.

Founded in 2011, Adagene originated as a China-based biotech company and later established a U.S. presence to support global development and capital markets access. The company completed its initial public offering on the Nasdaq Global Market in 2021 under the ticker ADAG. Since inception, Adagene has evolved from a discovery-focused enterprise into a clinical-stage organization with multiple oncology programs advancing through early- and mid-stage clinical development.

Business Operations

Adagene’s operations are organized around its proprietary technology platforms and its oncology pipeline. The company’s primary business segments include antibody discovery, preclinical development, and clinical development of immuno-oncology therapeutics. Revenue generation to date has primarily come from strategic collaborations and research agreements rather than product sales, as no therapies have yet received regulatory approval.

The company’s technology foundation includes the NEObody™ platform for masked antibody prodrug design and the POWERbody™ platform for optimizing antibody agonism and selectivity. Adagene conducts research and early development through its wholly owned subsidiary Adagene (Suzhou) Limited, while clinical development, regulatory strategy, and corporate functions are managed through its U.S. entity. The company has entered into collaboration agreements with large pharmaceutical partners, including Bristol Myers Squibb, to co-develop select immuno-oncology assets.

Strategic Position & Investments

Adagene’s strategic direction emphasizes advancing a focused pipeline of first- or best-in-class immunotherapies while selectively partnering programs to offset development risk and capital requirements. Key growth initiatives include progressing lead assets such as ADG126 and ADG116 through clinical trials and expanding the application of its masking and agonist antibody technologies to additional immune targets.

The company has made targeted investments in platform enhancement rather than large-scale acquisitions, reflecting its capital-efficient operating model. Notable strategic assets include partnered programs with Bristol Myers Squibb, which provided upfront payments and potential milestone-based funding. Adagene is also actively exploring emerging areas within immuno-oncology, including next-generation immune checkpoint modulation and conditionally activated biologics.

Geographic Footprint

Adagene operates across North America and Asia, with dual headquarters functions supporting its global strategy. Its U.S. operations are based in San Diego, California, which serves as the center for corporate leadership, investor relations, and clinical development activities. The company’s primary research and development facilities are located in Suzhou, China, a major biotechnology hub.

This cross-border structure enables Adagene to access international talent pools, conduct cost-efficient research, and run global clinical trials. The company’s clinical programs involve trial sites in multiple countries, reflecting its intent to pursue regulatory approvals in both Western and Asian markets.

Leadership & Governance

Adagene is led by a management team with experience spanning biotechnology research, global drug development, and capital markets. The leadership emphasizes scientific rigor, data-driven decision-making, and strategic partnering as core elements of the company’s governance and long-term vision.

Key executives include:

• Peter Luo – Co-Founder, President, and Chief Executive Officer
• Fu Xiong – Co-Founder and Chief Technology Officer
• Jennifer Rhyne – Chief Financial Officer
• Cindy Li – Chief Development Officer
• Jiacheng Liu – Chief Medical Officer

The board and executive team collectively guide Adagene’s strategy to translate its antibody engineering platforms into clinically meaningful cancer therapies while maintaining compliance with U.S. public company governance standards and international regulatory requirements.